When Broiler Drinking Water Hardness Exceeds 250 ppm CaCO₃: Soluble Powder Formulation Boundaries

The sodium salt of sulfachlorpyridazine is selected for drinking-water medications because the free acid exhibits limited aqueous solubility, whereas the sodium salt dissolves rapidly at pH ranges commonly found in poultry water systems. A standard water-soluble powder is formulated with sulfachlorpyridazine sodium at 300 g/kg active equivalent on a carrier of anhydrous lactose monohydrate, with 12% w/w sodium citrate dihydrate and 5% w/w anhydrous sodium carbonate as buffering and sequestering excipients. The addition ratio is set at 300 g/kg so that a 1 g powder dose in 1 L water produces a nominal 300 mg/L active solution. In field water containing more than 250 ppm CaCO₃, calcium ions compete with the sodium counterion, and insoluble calcium sulfachlorpyridazine can precipitate; the citrate fraction is therefore increased to 15% w/w when upstream water analysis reports hardness above this threshold.

Downstream manufacturing of this powder is performed in a 1,200 L ribbon blender operating at 15 rpm for 20 min after geometric pre-blending of the API with 10 kg carrier. The blend is discharged through a 0.25 mm stainless steel sieve and conveyed under dehumidified air with relative humidity held below 45%. The sodium salt is hygroscopic; filling is conducted in a room conditioned to 20–25°C and 35–40% RH to prevent caking and assay drift. Sachets are formed from laminated aluminum foil with polyethylene inner layer and sealed at 160–180°C, with fill weights of 100 g, 1 kg, and 5 kg. Terminal dosage forms are water-soluble powder sachets for oral solution preparation. Compliance for this dosage form includes 21 CFR 210/211 component testing, VICH GL18 residual solvent limits, ICH Q3D elemental impurity risk assessment, and HPLC assay according to Ph. Eur. 2.2.29. Dissolution acceptance is verified by adding 5 g powder to 500 mL water at 20°C and confirming complete dissolution within 2 min without visible precipitate.

What Limits Terminal Sterilization of 20% w/v Sulfachlorpyridazine Sodium Injections?

Injectable formulations are prepared as a 20% w/v solution of sulfachlorpyridazine sodium, corresponding to 200 g/L active. The manufacturing sequence begins by dissolving the API in Water for Injection at 35°C under nitrogen purging to minimize oxidative degradation. The pH is adjusted to 9.0–9.5 with 1 M sodium hydroxide; at lower pH the free acid may precipitate, and above 9.8 the sulfonamide ring becomes susceptible to base-catalyzed hydrolysis. Sodium metabisulfite 1 g/L is added as an oxygen scavenger. The bulk solution is filtered through a 0.45 µm prefilter and then a 0.22 µm PVDF membrane, followed by aseptic filling into 100 mL amber Type I borosilicate vials with nitrogen headspace.

The terminal sterilization decision depends on the thermal stability of the specific formulation and container-closure system. Where stability data demonstrate less than 0.5% related substance increase after autoclaving, a cycle of 121°C for 15 min with an F₀ greater than 12 min is applied. If the formulation shows pH-dependent hydrolysis during forced degradation at 90°C over 7 days, validated sterile filtration is used instead, and each batch is tested for sterility according to USP <71>, bacterial endotoxins according to USP <85>, and particulate matter according to USP <788>. Container closure integrity is assessed by vacuum decay per ASTM F2338-09. Terminal dosage form is a multi-dose injectable solution. Compliance additionally includes 21 CFR 211.94 for container-closure suitability, ICH Q3D for elemental impurities from Type I glass and elastomer stoppers, and VICH GL18 for residual solvents from the API. Addition ratio is 200 g/L active; no further dilution is required at the farm level, but the injectable is administered only after veterinary prescription and withdrawal-period verification.

In medicated feed production, sulfachlorpyridazine API is incorporated into a 10% w/w premix using a carrier composed of ground wheat bran and limestone flour at a 4:1 ratio. The carrier particle size is controlled to 250–600 µm, which balances dust reduction with homogeneous distribution. Before blending, 0.2% w/w food-grade mineral oil is sprayed onto the carrier to bind the API particles and reduce segregation during subsequent transport. The final premix is mixed in a 2,000 L ribbon blender for 15 min, after geometric dilution of the API into 25 kg carrier increments. Homogeneity is confirmed by sampling 10 points across the discharge and assaying by HPLC with a coefficient of variation not exceeding 5.0%. Downstream feed mills incorporate 2.5–5.0 kg premix per tonne of complete feed, resulting in 250–500 mg active per kilogram of feed. The terminal dosage form is a free-flowing medicated premix packed in 25 kg multiwall paper bags with an inner polyethylene liner. Compliance is governed by EU Regulation (EU) 2019/6 for veterinary medicinal products, Regulation (EC) No 183/2005 for feed hygiene, and Codex CAC/RCP 54-2004 for control of carry-over and batch separation.

Process failure modes observed on production lines include API segregation when carrier particle size distribution is too broad and assay drift when the mineral oil spray nozzle is worn or partially blocked. For this reason the blend is discharged through a 1.0 mm sieve and sampled at 10 locations; a loss-on-drying specification of ≤12% for wheat bran is set to avoid caking in silos. Residual moisture in the liners is tested by Karl Fischer titration with acceptance ≤0.5% water. No terminal sterilization is required, but the area is maintained at ≤60% RH and the product is released after assay, related substances, and heavy metals according to ICH Q3D.

Calf Bolus Compression Forces and Disintegration Thresholds

Tablets and capsules for calves and small ruminants require a formulation in which the API content is high enough to reduce dosing frequency but still permits robust compression. A direct-compression tablet core is formulated with sulfachlorpyridazine at 500 mg per 760 mg core, equivalent to 65.8% w/w API. The excipients consist of microcrystalline cellulose 25% w/w, sodium starch glycolate 2% w/w, magnesium stearate 0.5% w/w, and colloidal silicon dioxide 0.2% w/w. The API is milled to a particle size D90 of 25 µm before blending to improve content uniformity and dissolution. When granulation is required because the API has poor flowability, a high-shear granulator is used with a 4% w/v povidone K30 solution; the wet mass is dried in a fluid-bed dryer at inlet 55°C, outlet 32°C, to a loss on drying below 2.5%.

Compression is performed on a 16-station rotary tablet press at 18–22 kN, producing a target hardness of 7–9 kp and friability below 0.5% according to USP <1216>. The disintegration time is controlled below 15 min in water at 37°C per USP <701>. For encapsulated dosage, the same granulate is filled into size 0 gelatin capsules at 500 mg active per capsule. Terminal forms are film-coated 500 mg boluses and 500 mg capsules. Coating is applied as a 6% hydroxypropyl methylcellulose dispersion in a pan coater at 38°C product temperature. Compliance includes 21 CFR 211.65 equipment maintenance, USP <711> dissolution testing with 0.1 M hydrochloric acid at 37°C and 75 rpm, and ICH Q3D elemental impurity assessment for tablet cores.

Granulation Through a 0.8 mm Screen: Drying Inlet Limits and Friability Data

Oral granules for piglets and weaners are prepared by wet granulation to achieve a dosage form that disperses in milk replacer or water. The API addition ratio is 50 g/kg as sulfachlorpyridazine sodium, corresponding to 5% w/w. The carrier matrix contains lactose monohydrate 72% w/w, povidone K30 2% w/w, sodium citrate dihydrate 10% w/w, microcrystalline cellulose 9% w/w, and sodium chloride 2% w/w. The wet mass is extruded through a 0.8 mm screen in a basket extruder at 40 rpm, then spheronized at 800 rpm for 3 min. Drying is performed in a fluid-bed dryer with inlet air temperature not exceeding 55°C, because higher temperatures cause surface hardening and reduce dispersibility; outlet temperature is maintained at 30–34°C until loss on drying is below 2.5%.

The dried granules are sieved to a fraction between 0.71 mm and 1.40 mm, yielding a bulk density of 0.48–0.56 g/mL and friability below 0.3% when tested by tumbling 10 g of granules for 10 min at 25 rpm. The terminal dosage form is a 100 g sachet of oral granules. Dispersion acceptance is evaluated by adding 5 g granules to 200 mL water at 25°C and stirring at 100 rpm; complete dispersion is required within 3 min with no agglomerates retained on a 0.25 mm sieve. Compliance references include Ph. Eur. 2.2.29 for assay, ICH Q3D for elemental impurities, and VICH GL18 for residual solvents. Batch-to-batch variability in sieve fraction is minimized by controlling extruder screen wear; screen replacement is scheduled after every 80 batches or when granule shape becomes irregular.

A 100 mg/mL oral solution is manufactured by dissolving sulfachlorpyridazine sodium in purified water at 30°C under agitation at 300 rpm for 15 min; the final active concentration is 100 g/L. Potassium sorbate 0.15% w/w is added as a preservative, and the pH is adjusted to 8.5–9.0 with 1 M sodium hydroxide. Buffering with 0.5% w/w sodium bicarbonate prevents pH drift during storage in HDPE containers. The solution is filtered through a 1.0 µm polypropylene filter and filled into 1 L and 5 L high-density polyethylene bottles using an automated volumetric filler with an overfill tolerance of ±1%. The terminal dosage form is an oral solution for drinking-water or drench administration in poultry and calves.

The addition ratio of 100 g/L is selected to permit dilution at the farm level without handling bulk powder. Stability is monitored by assay and related substances under 25°C/60% RH for 24 months in the commercial pack. Compliance includes 21 CFR 210/211, ICH Q3D for extractable elements from container polyethylene, and VICH GL18 for residual solvents from the API. The filling line is sanitized between product campaigns to prevent cross-contact; rinse water is tested for sulfonamide residues by HPLC with a limit of detection below 0.1 ppm.